Nonarteritic Anterior Ischemic Optic Neuropathy

@article{Atkins2011NonarteriticAI,
  title={Nonarteritic Anterior Ischemic Optic Neuropathy},
  author={Edward J. Atkins},
  journal={Current Treatment Options in Neurology},
  year={2011},
  volume={13},
  pages={92-100}
}
  • E. J. Atkins
  • Published 2011
  • Medicine
  • Current Treatment Options in Neurology
Opinion statementCurrently there is no generally accepted, well-proven treatment for nonarteritic anterior ischemic optic neuropathy (NAION). Most proposed treatments are empirical and include antithrombotics, vasodynamic agents, treatments aimed at reducing optic disc edema, and various neuroprotective strategies. Most potential treatments have been inadequately studied, prematurely embraced, or prematurely discarded. Evidence for antithrombotic agents is lacking, and small vessel arterial… Expand
Steroids in the treatment of nonarteritic anterior ischemic optic neuropathy
TLDR
A meta-analysis of all available published studies found that steroids do not significantly improve visual acuity in NAION, and attempts at reversing ischemia should not involve the use of steroids. Expand
The Pathogenesis of Nonarteritic Anterior Ischemic Optic Neuropathy
TLDR
Primate and nonprimate animal models of NAION differ from the human pattern ofNAION in the duration of the disease course, as well as the anatomy. Expand
Non-Arteritic Anterior Ischemic Optic Neuropathy and Factor V Leiden
TLDR
It is suggested that physicians consider prothrombotic disorders when evaluating patients with AION, especially in atypical cases or cases occurring in young patients without classic factors of cardiovascular risk. Expand
Translational Preclinical Research may Lead to Improved Medical Management of Non-Arteritic Anterior Ischemic Optic Neuropathy
TLDR
The process leading to non-arteritic anterior ischemic optic neuropathy (NA-AION) appears to be complex and multi-factorial (8), and the exact cause is still unknown. Expand
Aspirin Following Non-arteritic Ischaemic Optic Neuropathy—A Systematic Review and Meta-analysis
TLDR
Data suggest a benefit of aspirin in prevention of second eye NAION, but the evidence is weak and a multi-centre randomized controlled trial recruiting 750 patients is unlikely to be feasible. Expand
Non-arteritic anterior ischaemic optic neuropathy secondary to menorrhagia in a young healthy woman
TLDR
A 20-year-old healthy woman, who presented on the third day of a heavy menstrual cycle with hypovolaemic shock, develops right optic atrophy with persistent visual field defect despite an improved haemoglobin level of 10.5 g/dL. Expand
Assessment of peripapillary vessel density in acute non-arteritic anterior ischemic optic neuropathy
TLDR
Eyes with NAION have decreased peripapillary vessel density with peripAPillary vascular dilatation and tortuosity as assessed by OCTA. Expand
Clinical profile of patients with nonarteritic anterior ischemic optic neuropathy presented to a referral center from 2003 to 2008.
TLDR
Characteristics of nonarteritic anterior ischemic optic neuropathy patients in a population of Iranian patients were similar to nonarterites anterior isChemic optic Neuropathy as described in previous studies, with the exception of higher proportion of younger patients and a higher propensity for diabetes. Expand
Nonarteritic anterior ischemic optic neuropathy in young patients.
TLDR
It is observed that age did not play a significant role in prognosis of NAION, and diabetes is an increased risk for NAion in the young age group, and HT for NAION in the older group. Expand
Efficacy of Vincamine treatment in a rat model of anterior ischemic optic neuropathy.
TLDR
Vincamine can rescue RGC death and reduce the number of apoptotic cells and can be an effective therapy method for NAION according to the PI3K/Akt/eNOS signaling pathway. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 42 REFERENCES
Treatment of nonarteritic anterior ischemic optic neuropathy.
TLDR
Most treatments proposed for NAION are empirical and include a wide range of agents presumed to act on thrombosis, on the blood vessels, or on the disk edema itself, while therapies aimed at secondary prevention of fellow eye involvement in NAION remain of unproven benefit. Expand
Aspirin therapy in nonarteritic anterior ischemic optic neuropathy.
TLDR
A possible short-term but little or no long-term benefit to aspirin in reducing the risk of nonarteritic anterior ischemic optic neuropathy in the fellow eye is suggested, but this finding must be viewed with caution because this study was not conducted prospectively with a controlled protocol. Expand
Treatment of nonarteritic anterior ischemic optic neuropathy with intravitreal bevacizumab.
TLDR
The first use of intravitreal bevacizumab for the treatment of NAION demonstrating a rapid and substantial reduction in optic nerve head edema and an unanticipated level of visual recovery is reported. Expand
Pathogenesis of nonarteritic anterior ischemic optic neuropathy.
  • A. Arnold
  • Medicine
  • Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • 2003
TLDR
The pathogenesis of idiopathic nonarteritic ischemic optic neuropathy includes features of structurally crowded optic discs, laminar and retrolaminar regions are the most common locations for infarction, and diabetes is the most consistently identified vasculopathic risk factor. Expand
Ipsilateral recurrence of nonarteritic anterior ischemic optic neuropathy.
TLDR
It is indicated that nocturnal diastolic arterial hypotension may be a risk factor for recurrence of nonarteritic anterior ischemic optic neuropathy in the same eye; however, since this is a multifactorial disease, other so far unknown risk factors may also play a role. Expand
Erectile dysfunction drugs and nonarteritic anterior ischemic optic neuropathy.
TLDR
In response to a recent flurry of lay press coverage about he possible association of NAION and sildenafil (Viagra), the Food and Drug Administration has approved labeling for these drugs to include information on NAION. Expand
Intravitreal triamcinolone acetonide injection for acute non‐arteritic anterior ischaemic optic neuropathy *
TLDR
Intravitreal triamcinolone injection may offer help in limiting the damage in this small group of patients with a relatively short history of visual loss due to NAION. Expand
Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy
TLDR
It is suggested that NA-AION eyes treated during the acute phase with systemic corticosteroids resulted in a significantly higher probability of improvement in visual acuity and visual field than in the untreated group. Expand
Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial.
TLDR
The baseline findings are derived from a selected population of patients with NAION who were eligible for the IONDT and provide the first description of NAION from a large prospective study that used a standard definition ofNAION and only included patients who were identified within 2 weeks of the onset of symptoms. Expand
The effect of aspirin on the visual outcome of nonarteritic anterior ischemic optic neuropathy.
TLDR
Aspirin use does not improve the visual outcome of patients with nonarteritic anterior ischemic optic neuropathy and additional studies are needed to further elucidate this issue. Expand
...
1
2
3
4
5
...